Literature DB >> 33442183

Case Report of a Pituitary Metastasis from Lung Adenocarcinoma Masquerading as Pituitary Adenoma.

Radhamani Rajakumar1, Ijaz Hallaj Rahmatullah1, Anilah Abdul Rahim1.   

Abstract

Metastasis to the pituitary gland is an unusual situation in clinical practice and is typically observed in those with underlying malignancy with breast and lung being the commonest primary site. However, we report a case of an apparently well 49-year-old female with metastatic lung adenocarcinoma who presented with visual disturbance and diabetes insipidus related to pituitary metastasis as an initial presentation.
© 2020 Journal of the ASEAN Federation of Endocrine Societies.

Entities:  

Keywords:  diabetes insipidus; lung adenocarcinoma; pituitary metastasis

Year:  2020        PMID: 33442183      PMCID: PMC7784236          DOI: 10.15605/jafes.035.01.24

Source DB:  PubMed          Journal:  J ASEAN Fed Endocr Soc        ISSN: 0857-1074


INTRODUCTION

Cancers metastatic to the pituitary gland are uncommon and account for only 1.8% of all metastases and 1% of all pituitary cancers.[1] The breast and lung are the most frequent primary sites. Although the majority of patients are asymptomatic and often diagnosed at autopsy, two of the largest reported series noted that symptoms from the pituitary metastasis were the initial manifestation of metastatic disease in over half of the patients.[2,3] Diabetes insipidus was by far the most frequent symptom, occurring in 45% of patients, followed by optic nerve dysfunction (28%); anterior pituitary dysfunction (24%); palsies of cranial nerves III, IV, or VI (22%); and headache (16%).[4]

CASE

A 49-year-old female with no significant medical history presented with one-month history of progressive peripheral vision loss and headache. She had also experienced polydipsia with polyuria and further history revealed that she was amenorrhoeic for one year. Otherwise, she has no respiratory or constitutional symptoms. Physical examination was unremarkable except that visual field examination confirmed bitemporal hemianopia (Figure 1). A subsequent cranial magnetic resonance imaging (MRI) scan displayed a lobulated heterogeneous enhancing mass approximately 1.7 x 1.9 x 2.0 cm arising from the sella turcica with suprasellar extension and compression of the optic chiasma (Figure 2). Initial laboratory tests showed normal blood count, Na: 144 mmol/L (reference value [RV]:136-145), K: 4.1 mmol/L (RV: 3.5-4.4), and creatinine: 52 umol/L (RV: 44-80). Serum osmolality: 365 mOsm/kg (RV: 275-295) and urine osmolality: 66 mOsm/kg (RV: 300-900) taken during the polyuric phase were consistent with diabetes insipidus. Hormonal evaluation demonstrated insufficiencies of the corticotropic, thyroid and gonadotropic axis. (Table 1). She was started on hormonal replacement therapy (T. Hydrocortisone 10 mg BD, L-Thyroxine 25 mcg OM and T. Desmopressin 0.1 mg BD).
Figure 1

Humphrey visual field test results for patient’s left (A) and right (B) eyes, confirming a dense bitemporal visual loss.

Figure 2

Magnetic resonance imaging of the pituitary showing lobulated heterogenous sellar mass with suprasellar extension and compression of optic chiasm, sagittal view in A and coronal view in B.

Table 1

Initial hormon al evaluation

Hormone (unit)ResultsReference Value
LH (IU/L)0.12.4-12.6
FSH (IU/L)1.43.5-12.5
PRL (ug/L)6.734.79-23.30
IGF-1 (ug/L)93103-310
ACTH (pmol/L)<1.1<10.2
Cortisol (nmol/L)43.6171-536
FT4 (pmol/L)10.812-22
TSH (mIU/L)0.180.27-4.2

LH: luteinizing hormone, FSH: follicle-stimulating hormone, PRL: prolactin, IGF-1: insulin like growth factor -1, ACTH: adrenocorticotropic hormone, T4: thyroxine, TSH: thyroid stimulating hormone

Initial hormon al evaluation LH: luteinizing hormone, FSH: follicle-stimulating hormone, PRL: prolactin, IGF-1: insulin like growth factor -1, ACTH: adrenocorticotropic hormone, T4: thyroxine, TSH: thyroid stimulating hormone Humphrey visual field test results for patient’s left (A) and right (B) eyes, confirming a dense bitemporal visual loss. Magnetic resonance imaging of the pituitary showing lobulated heterogenous sellar mass with suprasellar extension and compression of optic chiasm, sagittal view in A and coronal view in B. The patient underwent endoscopic transsphenoidal pituitary surgery with resection of the mass. The postoperative recovery was uneventful and was discharged well with hormonal replacement therapy. She was seen in clinic one week postoperatively with the complaint of left shoulder pain. Left shoulder x-ray showed pathological fracture of the left proximal humerus (Figure 3) and chest radiography (Figure 4) showed suspicious left lung nodule. A chest radiography was not done pre-operatively as there were no prior clinical indications. Pituitary histopathological analysis was later reported as metastatic adenocarcinoma. CT of the thorax, abdomen and pelvis revealed a mass (3.3 x 4.9 x 3.6 cm) at the posterior basal segment of left lower lobe (Figure 4) with multiple lung nodules of varying size noted bilaterally, enlarged mediastinal and hilar lymph nodes, and lytic lesion at proximal humerus and L5 vertebral body.
Figure 3

Pathological fracture of the left proximal humerus.

Figure 4

Suspicious left lung nodule.

Pathological fracture of the left proximal humerus. Suspicious left lung nodule. CT scan of the thorax revealed a mass (3.3 x 4.9x 3.6 cm) at the posterior basal segment of left lower lobe. Subsequently, patient underwent CT guided biopsy of the left lung mass. The histopathological analysis was consistent with pulmonary adenocarcinoma and the immunohistochemistry results were positive for cytokeratin 7 (CK7) and thyroid transcription factor 1 (TTF1) and negative for CK20 and thyroglobulin. Patient underwent stereotactic radiation therapy to the pituitary mass and was started on oral chemotherapy gefitinib.

DISCUSSION

Pituitary adenoma is the most common cause of pituitary masses, constituting approximately 10% of all intracranial neoplasms. Pituitary gland metastasis accounts for only approximately 1% of all pituitary tumours in previous serial studies.[5] Breast and lung tumours are the most common primary sites of malignant metastases to the pituitary gland, but other sites such as the gastrointestinal tract, prostate, kidney, thyroid, and pancreas have also been reported.[6] Majority of the pituitary metastases are clinically silent and only 6.8% of cases are symptomatic.[7] The most common presentations include diabetes insipidus (DI), visual field defects and hypopituitarism. DI is much more common in cases of pituitary metastases than in pituitary adenoma. Nearly 70% of symptomatic patients with pituitary metastases present with DI, whereas the rate of diabetes insipidus in patients with pituitary adenomas is less than 1%.[8] Differentiating a pituitary metastasis from a pituitary adenoma is often difficult, as the clinical and radiologic findings are often nonspecific.[9] Clinically, one helpful differentiating factor is the presence of DI, which is much more common in pituitary metastases than pituitary adenomas. The most characteristic imaging feature of a pituitary metastasis is enlargement or enhancement of the pituitary stalk with a pituitary mass.[10] In our patient, she had pituitary metastases from lung adenocarcinoma and her initial presentation was visual field defect and diabetes insipidus. Her imaging showed typical snowman shape appearance of a pituitary adenoma. However, with no previous malignant history, clinical suspicion of pituitary metastases was low.

CONCLUSION

Pituitary metastases are rare but should be included in the differential diagnosis of invasive sellar lesions with pituitary stalk involvement, especially if it is associated with diabetes insipidus.
  9 in total

1.  Unusual presentations of lung cancer: Case 1. Diabetes insipidus as the initial manifestation of non-small-cell lung cancer.

Authors:  Pavan Reddy; Gregory P Kalemkerian
Journal:  J Clin Oncol       Date:  2002-12-01       Impact factor: 44.544

Review 2.  Clinical review: Pituitary carcinoma: difficult diagnosis and treatment.

Authors:  Anthony P Heaney
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

Review 3.  Differential diagnosis of sellar masses.

Authors:  P U Freda; K D Post
Journal:  Endocrinol Metab Clin North Am       Date:  1999-03       Impact factor: 4.741

4.  Clinicopathologic review of 88 cases of carcinoma metastatic to the putuitary gland.

Authors:  R J Teears; E M Silverman
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

Review 5.  Classification and pathology of pituitary tumors.

Authors:  George Kontogeorgos
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

6.  Metastatic tumors of the sella turcica masquerading as primary pituitary tumors.

Authors:  C L Branch; E R Laws
Journal:  J Clin Endocrinol Metab       Date:  1987-09       Impact factor: 5.958

Review 7.  Metastases to the pituitary gland.

Authors:  Daniel R Fassett; William T Couldwell
Journal:  Neurosurg Focus       Date:  2004-04-15       Impact factor: 4.047

8.  Symptomatic pituitary metastases.

Authors:  A Morita; F B Meyer; E R Laws
Journal:  J Neurosurg       Date:  1998-07       Impact factor: 5.115

9.  Breast cancer metastatic to the pituitary gland: a case report.

Authors:  Gian Paolo Spinelli; Giuseppe Lo Russo; Evelina Miele; Natalie Prinzi; Federica Tomao; Manila Antonelli; Felice Giangaspero; Valeria Stati; Martina Strudel; Silverio Tomao
Journal:  World J Surg Oncol       Date:  2012-07-09       Impact factor: 2.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.